Cowen Starts Corvus Pharmaceuticals (CRVS) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
Go back to Cowen Starts Corvus Pharmaceuticals (CRVS) at Outperform
April 19, 2016 6:47 AM EDT
BTIG initiated coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $22.00. Analyst Hartaj Singh is bullish on management and lead compound CPI-444.
"The company has two most important characteristics that we look for in early-stage biotech companies, (1)... More
April 18, 2016 7:26 AM EDT
Guggenheim initiated coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Buy rating and a price target of $24.00.
For an analyst ratings summary and ratings history on Corvus Pharmaceuticals click here. For more ratings news on Corvus Pharmaceuticals click here.
Shares of Corvus Pharmaceuticals closed at $15.61 yesterday.
...
More
April 18, 2016 6:39 AM EDT
Credit Suisse initiates coverage on Corvus Pharmaceuticals (NASDAQ: CRVS) with a Outperform rating and a price target of $25.00.
Analyst V. Divan commented, "We see CRVS as a compelling earlystage immuno-oncology (I-O) opportunity that is relatively higher risk but that also offers a potentially high reward. CRVS's lead compound,... More
